VEGF121 Protein (AA 207-327)

Produktnummer ABIN2666678

Produktdetails

Target: VEGF121 (Vascular Endothelial Cell Growth Factor 121 (VEGF121))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: AA 207-327

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Flow Cytometry (FACS)

Reinheit: > 98 % , as determined by Coomassie stained SDS-PAGE.

Sterilität: 0.22 μm filtered

Endotoxin-Niveau:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: ED50 = 0.5 - 2.5 ng/ml, corresponding to a specific activity of 0.4 - 2.0 x 106 units/mg, as determined by the dose dependent stimulation of HUVEC cells proliferation.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Rekonstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 5 mM citric acid, 5 mM NaHPO4, 0.15 M NaCl, pH 4.0.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Antigendetails

Target: VEGF121 (Vascular Endothelial Cell Growth Factor 121 (VEGF121))

Andere Bezeichnung: VEGF-121 (VEGF121 Produkte)

Hintergrund: VEGF was initially identified in conditioned medium from bovine pituitary follicular cells. VEGF-A belongs to the VEGF family, which has the following members: VEGF-A, VEGF-B, VEGF-C (VEGF-2), VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs such as T.f. ( Trimeresurus flavoviridis) and svVEGF (called VEGF-F) have been described. VEGFA is alternatively spliced to generate variants with different number of amino acids such as VEGFA121, VEGFA145, VEGFA165, and VEGFA189. While VEGFA121 is freely diffusible and did not bind to neurophilis (NRPs) nor heparin sulphate, VEGFA165 and VEGFA189 bind to both, resulting in retention on the cell surface or in the extracellular matrix. VEGF-A is highly expressed in solid tumors generated in breast, lung, renal, colorectal and liver tissues. VEGF has strong vascular permeability activity and significantly contributes to the formation of ascites tumors. VEGF can act as a direct proinflammatory mediator during the pathogenesis of rheumatoid arthritis (RA) and protect rheumatoid synoviocytes from apoptosis, which contributes to synovial hyperplasia. VEGF is expressed in synovial macrophages and synovial fibroblasts in RA patients. Also, VEGF is associated with age-related macular degeneration (AMD). AMD is due to neovascularization that originates from endothelial cells in the choroid that grow into neurosensory retina as choroidal neovascularization (CNV).

Molekulargewicht: The 121 amino acid recombinant protein has a predicted molecular mass of approximately 14 kDa. The DTT-reduced protein migrates at approximately 20 kDa and non-reduced protein migrates at 40 kDa by SDS-PAGE. The N-terminal amino acid is Alanine.